This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytara...
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
Age: 18 - 59 years
Gender: All